- Home
- MLYS vs FAX Comparison
MLYS vs FAX Comparison
Compare MLYS & FAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MLYS | FAX |
|---|---|---|
| Founded | 2019 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 632.9M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | MLYS | FAX |
|---|---|---|
| Price | $35.70 | $15.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $47.33 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 833.6K |
| Earning Date | 02-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.09% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.24 | $2.33 |
| 52 Week High | $47.65 | $2.84 |
Technical Indicators
Market Signals| Indicator | MLYS | FAX |
|---|---|---|
| Relative Strength Index (RSI) | 38.58 | 46.66 |
| Support Level | $34.21 | $15.20 |
| Resistance Level | $36.61 | $15.75 |
| Average True Range (ATR) | 1.35 | 0.13 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 35.56 | 15.71 |
Price Performance
Historical ComparisonAbout MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
About FAX abrdn Asia-Pacific Income Fund Inc.
Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.